Treatment Duration on OLYSIO® | HCP
No treatment-stopping rules apply to the combination of OLYSIO® with SOF.
Patients with HCV GT1a and Q80K polymorphism
Prior to initiation of treatment with OLYSIO® + SOF, screening patients infected with
HCV GT1a for the presence of virus with the NS3 Q80K polymorphism is not strongly
recommended but may be considered